<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">



External stories on biodesix

GenomeWeb: Biodesix Sees Expansion into Genomics Driving Adoption of VeriStrat Proteomic Test

Adoption of GeneStrat by oncologists is helping to drive greater adoption of VeriStrat, Biodesix's proteomic test for assessing a patient's prognosis and predicting response to drug treatment.

Innovationews: New Clinical Findings Show Diagnostic Advances for Novel Drug

The results on this study are particularly exciting, as they suggest that we may be able to identify patients most likely to benefit from anti-PD-1 therapies.

Biodesix: 216 of the Inc500 for 2015

Biodesix listed at 216 in the Inc500 for 2015

Biodesix Launches GeneStrat Targeted Liquid Biopsy Mutation Test for Patients with Advanced Lung Cancer

Genestrat: a targeted liquid biopsy for patients with NSCLC. Blood test with 72 hour turnaround time.

United Healthcare Approves Coverage for Biodesix’ VeriStrat Test

Biodesix' VeriStrat test has won approval and coverage from United HealthCare.

Study: Better NSCLC Outcomes with Proteomic Test

Study: better NSCLC outcomes with proteomic test

AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study

Results from a analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.

New Technology for the Proteomic Age (Nature Publication)

Biodesix in Nature - Proteomic technology

Biodesix’s VeriStrat Test for Cancer Treatment Passes Phase 3 Trial (Xconomy)

Veristart passed a key clinical trial that shows it can give physicians a better idea of what to do next after the first round of treatment for NSCLC.

Putting Lung Cancer in the Bullseye (Breakthroughs)

Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. It all comes down to a blood test called VeriStrat.